1-7 of 7
Ann G. Zauber
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

The Influence of UGT1A6 Variants and Aspirin Use in a Randomized Trial of Celecoxib for Prevention of Colorectal Adenoma

Free
Andrew T. Chan, Meier Hsu, Ann G. Zauber, Ernest T. Hawk, Monica M. Bertagnolli
Journal: Cancer Prevention Research
Cancer Prev Res (Phila) (2012) 5 (1): 61–72.
https://doi.org/10.1158/1940-6207.CAPR-11-0337
Published: 03 January 2012
View articletitled, The Influence of UGT1A6 Variants and Aspirin Use in a Randomized Trial of Celecoxib for Prevention of Colorectal Adenoma
Open the PDF for The Influence of UGT1A6 Variants and Aspirin Use in a Randomized Trial of Celecoxib for Prevention of Colorectal Adenoma in another window
Includes: Supplementary data
Journal Articles

C-reactive Protein and Risk of Colorectal Adenoma According to Celecoxib Treatment

Free
Andrew T. Chan, Camelia S. Sima, Ann G. Zauber, Paul M. Ridker, Ernest T. Hawk, Monica M. Bertagnolli
Journal: Cancer Prevention Research
Cancer Prev Res (Phila) (2011) 4 (8): 1172–1180.
https://doi.org/10.1158/1940-6207.CAPR-10-0403
Published: 03 August 2011
View articletitled, C-reactive Protein and Risk of Colorectal Adenoma According to Celecoxib Treatment
Open the PDF for C-reactive Protein and Risk of Colorectal Adenoma According to Celecoxib Treatment in another window
Includes: Supplementary data
Journal Articles

Statin Use and Colorectal Adenoma Risk: Results from the Adenoma Prevention with Celecoxib Trial

Free
Monica M. Bertagnolli, Meier Hsu, Ernest T. Hawk, Craig J. Eagle, Ann G. Zauber
Journal: Cancer Prevention Research
Cancer Prev Res (Phila) (2010) 3 (5): 588–596.
https://doi.org/10.1158/1940-6207.CAPR-09-0271
Published: 04 May 2010
View articletitled, Statin Use and Colorectal Adenoma Risk: Results from the Adenoma Prevention with Celecoxib Trial
Open the PDF for Statin Use and Colorectal Adenoma Risk: Results from the Adenoma Prevention with Celecoxib Trial in another window
Includes: Supplementary data
Journal Articles

Five-Year Efficacy and Safety Analysis of the Adenoma Prevention with Celecoxib Trial

Free
Monica M. Bertagnolli, Craig J. Eagle, Ann G. Zauber, Mark Redston, Aurora Breazna, KyungMann Kim, Jie Tang, Rebecca B. Rosenstein, Asad Umar, Donya Bagheri, Neal T. Collins, John Burn, Daniel C. Chung, Thomas Dewar, T. Raymond Foley, Neville Hoffman, Finlay Macrae, Ronald E. Pruitt, John R. Saltzman, Bruce Salzberg, Thomas Sylwestrowicz, Ernest T. Hawk, for the Adenoma Prevention with Celecoxib Study Investigators
Journal: Cancer Prevention Research
Cancer Prev Res (Phila) (2009) 2 (4): 310–321.
https://doi.org/10.1158/1940-6207.CAPR-08-0206
Published: 06 April 2009
View articletitled, Five-Year Efficacy and Safety Analysis of the Adenoma Prevention with Celecoxib Trial
Open the PDF for Five-Year Efficacy and Safety Analysis of the Adenoma Prevention with Celecoxib Trial in another window
Includes: Supplementary data
Journal Articles

Prostaglandin Inhibition and Cardiovascular Risk: Maybe Timing Really Is Everything

Free
Monica M. Bertagnolli, Ann G. Zauber, Scott Solomon
Journal: Cancer Prevention Research
Cancer Prev Res (Phila) (2009) 2 (3): 195–196.
https://doi.org/10.1158/1940-6207.CAPR-08-0245
Published: 05 March 2009
View articletitled, Prostaglandin Inhibition and Cardiovascular Risk: Maybe Timing Really Is Everything
Open the PDF for Prostaglandin Inhibition and Cardiovascular Risk: Maybe Timing Really Is Everything in another window
Includes: Supplementary data
Journal Articles

Comment re: “Sporadic Aberrant Crypt Foci Are Not a Surrogate Endpoint for Colorectal Adenoma Prevention” and “Aberrant Crypt Foci in the Adenoma Prevention with Celecoxib Trial”

Free
Ann G. Zauber, Monica M. Bertagnolli, for the APC Trial Investigators
Journal: Cancer Prevention Research
Cancer Prev Res (Phila) (2008) 1 (3): 216.
https://doi.org/10.1158/1940-6207.CAPR-08-0131
Published: 25 July 2008
View articletitled, Comment re: “Sporadic Aberrant Crypt Foci Are Not a Surrogate Endpoint for Colorectal Adenoma Prevention” and “Aberrant Crypt Foci in the Adenoma Prevention with Celecoxib Trial”
Open the PDF for Comment re: “Sporadic Aberrant Crypt Foci Are Not a Surrogate Endpoint for Colorectal Adenoma Prevention” and “Aberrant Crypt Foci in the Adenoma Prevention with Celecoxib Trial” in another window
Journal Articles

Aberrant Crypt Foci in the Adenoma Prevention with Celecoxib Trial

Free
Nancy L. Cho, Mark Redston, Ann G. Zauber, Adelaide M. Carothers, Jason Hornick, Andrew Wilton, Stephen Sontag, Norman Nishioka, Francis M. Giardiello, John R. Saltzman, Chris Gostout, Craig J. Eagle, Ernest T. Hawk, Monica M. Bertagnolli
Journal: Cancer Prevention Research
Cancer Prev Res (Phila) (2008) 1 (1): 21–31.
https://doi.org/10.1158/1940-6207.CAPR-07-0011
Published: 09 June 2008
View articletitled, Aberrant Crypt Foci in the Adenoma Prevention with Celecoxib Trial
Open the PDF for Aberrant Crypt Foci in the Adenoma Prevention with Celecoxib Trial in another window
Includes: Supplementary data